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Summary 
The potential of interleukin 7 (Ib7) to induce an antitumor response in vivo was analyzed. Therefore, 
the IL-7 gene was expressed in the plasmacytoma cell line J558L. Although the growth of Ib7- 
producing cells was not retarded in vitro, the II~7-producing ceils were completely rejected upon 
injection into mice. Tumor rejection was observed only in syngeneic but not in nude mice. The 
tumor-suppressive effect could be abolished by the parallel injection of an anti-Ib7 monoclonal 
antibody. Immunohistochemical analysis revealed IL-7-dependent infiltration of the tumor tissue 
by CD4 + and CD8 + T  lymphocytes, and also type 3 complement receptor-positive (CR3 +) 
cells, predominantly macrophages. Depletion of T  cell subsets in tumor-bearing mice showed 
the absolute dependence of the antitumor response on CD4 + cells, whereas tumor rejection was 
unaffected by depletion of CD8 + ceils. In addition to CD4 + cells, CR3 + cells were also needed 
for tumor rejection. The antitumor effect of IL-7 was confirmed by expression of the Ib7 gene 
in a second tumor cell line of different cellular origin. Together, our results demonstrate that 
a high local Ib7 concentration at the tumor site obtained by tumor cell-targeted gene transfer 
leads to tumor rejection involving a cellular mechanism that seems to be different from the ones 
observed in analogous experiments with other cytokines. 
I 
L-7 has  originally been described as a growth factor for 
. B cell progenitors (1, 2) and subsequently shown to be 
a pleiotropic cytokine that has both proliferative and differen- 
tiative effects on ceils of various lineages in vitro. In partic- 
ular, Ib7 supports proliferation of mature CD4 + and CD8 § 
cells (3-5), and induces differentiation of cytotoxic T  cells, 
LAK cell activity (6-8), and tumoricidal activity of macro- 
phages (9). We have investigated the possibility as to whether 
any of the IL-7-induced cellular functions alone or in concert 
could induce an antitumor reaction in vivo. For this purpose, 
tumor cells were genetically engineered to produce II-7 in 
order to provide a locally increased cytokine concentration 
upon injection into mice. This experimental approach has 
been successfully used for the analysis of the antitumor effects 
of II.-2 (10-12), Ib4 (13, 14), IFN-3r (15, 16), TNF (17-19), 
and granulocyte CSF (G-CSF) 1 (20).  In search of antitumor 
activities in vivo, tumor cell-targeted cytokine gene transfer 
not only circumvents some of the practical problems of sys- 
temical application  (short half-life, effective doses at the tumor 
site, toxicity) but it also offers the advantage of a more physi- 
1 Abbreviations  used in  this paper:  G-CSF, granulocyte  CSF;  LTR,  long 
terminal repeat; MoMuLV, Moloney murine leukemia virus. 
ological mode of action if an immune response is considered 
at least in part as a locally directed process (21). The analysis 
of the antitumor responses induced by different cytokines has 
revealed characteristical differences in the effector mechanisms. 
The mechanism induced by some cytokines merely reflected 
their known function. For instance, the roles of cytotoxic 
CD8 +  T  cells  during  the II.,2-induced immune response 
(10) or the activation of granulocytes by G-CSF-producing 
tumor cells  (20)  were consistent with known activities of 
these cytokines. In contrast, the possible involvement ofmac- 
rophages and eosinophiles in the II:4-induced antitumor re- 
sponse was rather unexpected (13). However, not all cytokines 
are capable of inducing an antitumor response when produced 
by the tumor cells. Notably, the parallel expression of Ib6 
and TNF genes in the same tumor cell line showed that Ib6 
did not cause tumor suppression, whereas TNF was rather 
effective (17). In contrast to the above-mentioned immuno- 
stimulator)" antitumor effects of some cytokines, transfer of 
the TGF-3 gene into an immunogeneic tumor cell line led 
to the inhibition of a tumor-specific immune response (22). 
Due to these opposite effects of cytokines on tumor growth 
(reviewed in reference 23), it seems to be necessary to syste- 
matically study cytokines with respect to their potential an- 
titumor activity and to elaborate the different cytokine-induced 
immunological responses. 
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Cell Lines.  J558L is a heavy chain loss variant of the BALB/c 
plasmacytoma J558 (24) and was cultured as described (14). TS/A 
is a nonimmunogeneic mammary adenocarcinoma cell line derived 
from BALB/c AnN mice (25). TS/A cells were cultured in RPMI 
1640,  10%  FCS,  2 mM glutamine,  and antibiotics. 
Construction of  lL 7 Gene Expression Vectors  and Gene Transfer  Ex- 
periments.  The mouse IL-7 cDNA was  isolated  by PCR using 
primers containing the translation start signal (5' GAC TGG ATC 
CAC CTC CCG CAG ACC ATG TTC CAT G 3') and the trans- 
lation stop signal (5' TAC TAC GGA TCC TGT TTA TAT ACT 
GCC CTT CAA AAT TTT 3') (2).  For PCR,  total RNA was 
extracted from mouse thymocytes and 1 #g was reverse transcribed 
into cDNA using random primers and Moloney murine leukemia 
virus (MoMuLV) reverse transcriptase  (Gibco Laboratories,  Grand 
Island,  NY;  Bethesda Research  Laboratories,  Bethesda,  MD) by 
standard procedures (26).  Amplification of the equivalent of 250 
ng RNA occurred in the presence of 200/~M dNTP, 10 mM Tris- 
HC1, pH 8.3, 50 mM KC1, 1.5 mM MgC12, 1 mg/ml gdatin, 200 
nM of each sense and antisense primers, and 0.5 U Taq polymerase 
(Perkin-Elmer Corp., Norwalk, CT) in a 50-/~1 volume. The PCR 
was performed for 40 cycles (1 min at 94~  1.5 min at 60~  and 
2 rain at 72~  Cloning of the PCR product was facilitated by 
the presence of BamHI restriction sites located in the primers. The 
purified BamHI fragment was cloned into the plasmid pBAneo (27) 
by replacing the neomycin gene and into the plasmid pLTR. For 
the generation of pLTR, plasmid pAPtag-1 (28) was digested with 
BspMII and HpaI in order to get rid of the alkaline phosphatase 
gene. The vector fragment was blunt-ended with Klenow poly- 
merase, religated, and, subsequently,  the mouse IL7 cDNA frag- 
ment ofpBA-IL7 was subcloned as BamHI fragment into the BgllI 
site of pLTR (pLTR-IL-7). The sequence identity of the Ib7 frag- 
ment with the published mouse I1.-7 cDNA was confirmed by se- 
quence analysis. The two plasmids pBA-IL-7 and pLTR-Ib7, which 
contain the IL-7 gene under B-actin  or MoMuLV long terminal 
repeat (LTR) promotor control, were transfected into J558L and 
TS/A cells by electroporation using a Gene-Pulser (Bio-Rad Labora- 
tories,  Richmond, CA). 5  x  106 cells in 0.5 ml D-PBS (without 
Ca  2+  and Mg  2+) were pulsed in a 0.4-cm cuvette with  200 V, 
960 # Farad (J558L) or 350 V, 250/x Farad (TS/A cells). The trans- 
fection solutions contained a 10:1 molar ratio between the Ib7 con- 
structs  and  the  neomycin gene  containing  plasmid  pWL  neo 
(Stratagene,  La Jolla, CA). Transfected cells were selected for 2 wk 
in medium containing 1 mg/ml G418 (Gibco Laboratories; Bethesda 
Research Laboratories) and were subsequently cloned. 
Detection oflL.7 Activity.  Ib7 was measured by its ability to 
directly stimulate thymocytes (29).  Briefly, thymocytes of 4-wk- 
old C57 BL/6 mice were cultured for 72 h at a density of 5  x 
106 cells/ml in a 0.2-ml volume in a 96-well flat-bottomed micro- 
titer plate in RPMI 1640 containing 10% FCS, 50/xM 2-ME, 2 mM 
glutamine,  and  serial  dilutions  of standard  recombinant  mlb7 
(British Biotechnology, Oxford, UK) or conditioned medium of 
transfectants.  Cells were pulse labeled during the last 6 h of cul- 
turing with 0.5/~Ci [3H]thymidine (5 Ci/mmol sp act). Finally, 
cells were harvested onto glass fibre plates, and [3H]thymidine in- 
corporation was quantified by scintillation counting.  1 U of IL-7 
was defined as the amount of IL-7 required to obtain half-maximal 
proliferation (0.3 ng/ml rib7). Maximal proliferation resulted in 
12,000 cpm on the average; background was <500 cpm. Medium 
of transfectants was conditioned during a 48-h culture period at 
a concentration of 106 cells/ml. 
Analysis of Tumor Cell Growth.  Cells of exponentially growing 
cultures were harvested (in case of TS/A ceils by trypsinisation), 
washed three times in D-PBS, and injected in a volume of 0.2 ml 
subcutaneously in the neck of 6-wk-old female BALB/c or BALB/c 
nu/nu (Bomholtgard, Ry, Denmark) or BALB/cAnN mice (Charles 
River Breeding Laboratories, Sulzfeld, FRG). In some experiments, 
mice were injected subcutaneously at a shaved abdominal location 
in order to better monitor the early phase of tumor growth. Mice 
bearing a tumor >0.5 cm in diameter were considered as positive. 
Tumor size was determined as the mean of the largest  diameter 
and the diameter at fight angle. 
Antibody Treatment In Vivo.  4  x  106 cells were injected sub- 
cutaneously simultaneously with various mAbs. A rat anti-mouse 
1I.-7 mAb (IgG2b) (no. 1689-01; Genzyme, Cambridge, MA) was 
injected intravenously in doses of 200/~g/0.2 ml at days 0 (the day 
of tumor cell injection), 2, 4, 6, and 8 after tumor cell injection. 
This mAb was shown to completely neutralize 1 U of IL-7 activity 
in the thymocyte proliferation assay at a concentration of 0.1/zg/ml. 
Depletion of T cells in vivo was accomplished by administration 
of the following rat mAbs: 30-H12 (c~Thy-l.2; IgG2b) (30), GK1.5 
(c~CD4; IgG2b) (31), and 2.43 (crCD8; IgG2b) (32). These anti- 
bodies were used as ascites fluids, diluted in D-PBS to a concentra- 
tion of '~1 mg/ml.  0.5 ml of the respective  antibodies were in- 
jected intraperitoneally at days -1 and 7. This treatment led to 
the virtual absence of the respective cell population from the spleen 
until at least day 14 after tumor cell injection, as shown by flow 
fluorocytometric analysis (data not shown). The rat anti-mouse 
CR3 mAb 5C6 (IgG2b) (33) was injected at days 0, 2, 4, 6, 8, 
and 10 intraperitoneally at doses of 0.5 mg in 0.5 ml D-PBS. The 
rat mAb 23-378 (IgG2b) (unpublished) served as an isotype-matched 
control mAb in all experiments. 
Immunohistochemistry.  Tumors were removed at different time 
points, frozen immediately in liquid nitrogen, and stored at -80~ 
6-/~m frozen sections  were cut from the tissue,  fixed in acetone 
(30 min) and chloroform (30 min), and stained with the following 
rat mAbs (in TBS +  10% BSA): anti-CR3 mAb Mac-1 (IgG2b) 
(34), anti-CD4 mAb RM 4-5 (IgG2a; Paesel and Lord, Frankfurt, 
FRG), anti-CD8 mAb 53-6.7  (IgG2a; Becton Dickinson & Co., 
Heidelberg, FRG), and the control mAbs 23-7 (IgG2a) and 23- 
378  (IgG2b), followed by incubation with alkaline phosphatase- 
conjugated secondary (goat anti-rat IgG[H+L]; Dianova Ham- 
burg, FRG) and tertiary antibodies  (rabbit anti-goat IgG[H + L]; 
Dianova).  Incubation was performed for 30 rain, and the sections 
were washed three times in TBS between different incubation steps. 
Alkaline  phosphatase activity was visualized  by New Fuchsin as 
described  (35),  and sections  were counterstained by hemalaun. 
Results 
IL,7  Gene  Transfer and  Expression  in  Tumor Cell  Line 
J558L.  To generate II.,7-producing  tumor cell lines,  two 
plasmids were constructed that allow expression of IL-7 under 
the control of either the 3-actin promotor (pBA-ID7) or the 
MoMuLV-LTR (pLTR-IL-7) (Fig. 1). The plasmacytoma cell 
line J558L was  transfected with plasmid pBA-IL7 by elec- 
troporation  together  with  the  neomycin  gene  containing 
plasmid pWLneo. Transfectants were selected for G418 resis- 
tance, cloned, and analyzed for IL-7 activity in the superna- 
tant. Finally, three clones (J558-IL-7, J558-IL-7A, and J558- 
IL-7  l~  with levels of Ib7 activity between 4 and 65 U  were 
selected for further analysis  (Table  1).  In a parallel experi- 
ment,  J558L  cells  were  mock-transfected  with  plasmid 
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Figure 1.  Structure of lb7 expression vectors. In plasmid pLTR-IL-7, 
the mouse IL-7 (mlb7) is expressed by the MoMuLV LTR promoter as 
indicated by the arrow. In plasmid pBA-Ib7, mIL-7 is under the control 
of the/3-actin promoter (BA). 
pWLneo 0558-neo).  The IL-7 activity in the supernatant  of 
the pBA-IL-7 transfectants could be completely blocked by 
an anti-Ib7 mAb. Both, parental J558L and J558-neo  cells 
did not produce I1.-7. The Ib7-producing clones differed from 
parental J558L cells neither morphologically nor with respect 
to their in vitro growth kinetics. 
IL7 Production by Tumor Cells Leads to Tumor Rejection  in 
Syngeneic BALB/c but Not in Nude Mice.  The tumor growth 
of the Ib7-producing cell lines was compared to that of pa- 
rental or mock-transfected J558L cells. First, various numbers 
of cells were injected into mice. The tumorigenic potential 
of IL-7-producing clones markedly differed from parental and 
mock-transfectedJ558L  cells (Table 2). In syngeneic BALB/c 
mice, J558-IL-7 cells did not give rise to tumors at all if cell 
numbers up to 106 were injected, although all mice injected 
with 106 parental J558L cells developed a tumor. At higher 
cell doses, small tumors appeared at the same time as in mice 
injected with parental J558 cells, but these stopped growing 
and began to regress between days 8 and 12, and completely 
disappeared at the beginning of or during the third week. 
A second clone, J558-Ib7A, which produces a comparable 
amount of Ib7,  showed similar growth characteristics. In 
contrast, mice injected with J558-IL-7  l~  cells, which pro- 
duce "~10 times less II~7 than the two other clones, all de- 
veloped tumors, some of which disappeared after a much 
longer time than observed with J558-IL-7-injected animals 
or even progressively continued to grow (Table 2). This indi- 
cates that the tumorigenicity inversely correlates with the 
amount of IL-7 produced by the tumor cells. 
Table  1.  Expression of lL-7 in Transfected Cell Lines 
Expression vector  Cell line  IL-7 activity 
U/ml 
pBA-IL-7  J558-IL-7  50 
J558-IL-7A  65 
J558-1L-7  I~  4 
pLTR-IL-7  TS/A-IL-7  50 
pWLneo  J558-neo  - 
Table  2.  Tumorigenicity of  J558L Cells and Transfectants 
in Syngeneic BALB/c and Nude Mice 
Cell type  Injection dose 
No.  of mice 
with tumor/no. 
of injected mice* 
BALB/c  Nude 
x  I0  ~ 
J558L  4  5/5 
2  13/15 
1  5/5 
0.5  3/5 
0.25  2/5 
J558-IL-7  4  0/5 
2  0/25 
1  0/5 
0.5  015 
0.25  0/5 
J558-IL-7A  4  0/5 
2  0/5 
J558-IL-7  l~  2  3/10 
J558-neo  4  5/5 
2  5/5 
5/5 
5/5 
(3)#  5/5 
(6)*  5/5 
(3)*  5/5 
5/5 
(7)* 
* Mice were observed  up to 4 too. 
* Number of mice that  transiently  developed  tumors  that  disappeared 
later  on. 
u 
F- 
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10- 
0- 
|  J558L 
J558-1L7  + cdL7  mAb 
o  J558-1L7 +  control  rnAb 
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Figure 2.  Growth of  J558-IL-7 tumors in the presence of a mAb against 
IL-7. Groups  of five mice  were injected  subcutaneously  with 4  x  106 
JSSgL or J558-IL-7 cells, Mice injected with J558-IL7 cells received intra- 
venously either the anti-lb7 or the control mAb in intervals of 2 d from 
days 0 to 8 (arrows). Symbols represent  the mean tumor size of all mice 
in each group.  SD was <15%  in all cases. 
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 To determine whether indeed IL-7 was responsible for the 
tumor rejection, mice receiving J558-Ib7 cells were injected 
in parallel with a neutralizing  anti-Ib7 mAb. As shown in 
Fig.  2,  mice injected with J558-IL-7 cells  and  an  isotype- 
matched control antibody transiently developed tumors, which 
remained <0.5 cm in diameter and completely disappeared 
by the end of the second week after injection of the tumor 
cells.  In contrast,  mice receiving the anti-IL-7 mAb in par- 
alld to J558-Ib7 ceils developed tumors indistinguishable from 
those formed in mice injected with parental J558L cells during 
the first 2 wk. Then,  however, '~6-7 d after the last injec- 
tion of the antibody, tumors stopped growing most likely 
due to the clearance of the mAb and subsequently regressed, 
whereas J558L tumors continued to grow and the mice had 
to be killed.  After 4 wk,  the tumors of J558-Ib7-injected 
animals,  which had been grown to a size of >2 cm in di- 
ameter  up to day 14,  completely disappeared. 
In contrast to the results observed in syngeneic animals, 
the tumor incidence in nude mice injected with either the 
Ib7-producing  transfectants  or parental cells was the same 
(Table 2). This suggested a host-dependent rejection mecha- 
nism  most likely involving T  cells. 
Immunohistochemistry of the IL 7-dependent Cellular Tumor 
Infiltrate.  To investigate the cellular mechanism of the IL-7- 
induced tumor rejection, immunohistologic analysis was per- 
formed on days 4, 6, 9, and 11 after subcutaneous injection 
of 4  x  106 J558L or J558-IL-7 cells  (Fig.  3). The presence 
of T cells was assessed by staining sections of the tumor tissue 
with anti-CD4 and anti-CD8 mAbs. In J558L tumors, only 
occasionally did single cells stain positively with either anti- 
body, regardless of the stage of the tumor. However, in J558- 
Ib7 tumors, the frequency of CD4 + and CD8 + cells on day 
4 was already elevated and the number of either cell type pro- 
gressively increased after day 6. The frequency of the CD4 § 
as compared to the CD8 + cells in the tumor tissue appeared 
approximately equal at all observed time points. Furthermore, 
a  progressively  increasing  number  of  CR3 +  cells  both 
infiltrating  and surrounding  the J558-IL-7 tumor could be 
detected, whereas only a moderate staining was found in J558L 
tumors  (Fig.  3).  The  CR.3 +  cells  elevated  in  J558-IL-7 
tumors were morphologically identified to be predominantly 
macrophages,  whereas granulocytes that  are also stained by 
the anti-CK3 mAb were not significantly increased as com- 
pared  to J558L tumors. 
Analysis of the Cellular Mechanism of the IL,7-mediated Tumor 
Rejection.  Since the J558-IL-7 tumors failed to undergo re- 
jection in nude mice, and furthermore,  since immunohisto- 
logic  analysis  identified  both  CD8 §  and  CD4 +  T  cells 
during the tumor rejection, we further analyzed the contri- 
bution of either subset (Table 3; Fig 4). Depletion of both 
cell types by the anti-Thy-l.2 mAb resulted in the complete 
abrogation of the antitumor response (Fig. 4). The immuno- 
histological  analysis  in  Thy-l.2 §  cell-depleted  animals  re- 
vealed  the  absence  of CD4 +,  CD8 §  T  cells  and  macro- 
phages  in  the  J558-IL-7  tumor  tissue  (Table  4).  This 
demonstrates that the presence ofT cells is a prerequisite for 
the macrophages  to infiltrate  the tumor. 
Table  3.  Tumorigenicity  of  J558-lL-7 Cells in mAb-treated Mice 
No. of mice with tumor/ 
no.  of mice in experiment 
mAb treatment  Cell line  Exp.  1  Exp.  2  Exp.  3 
otThy-1.2  J558-IL-7  5/5  ND  5/5 
c~CD4  4/5  5/5  5/5 
c~CD8  0/5  0/5  0/5 
c~CR3  ND  ND  5/5 
Control  mAb  0/5  0/5  0/5 
-  J558L  5/5  4/5  5/5 
Likewise, depletion of CD4 + cells abrogated the tumor 
rejection (Fig. 4). However, a direct comparison of  J558-IL-7 
tumor growth  in Thy-l.2 vs.  CD4 + cell-depleted animals 
showed a slightly retarded growth in the latter animals. The 
immunohistology showed that CD4 § cells and macrophages 
were  virtually  absent  in  J558-IL-7  tumors  of  CD4 § 
cell-depleted mice, whereas CD8 + cells were not diminished 
as compared  to  untreated  mice  (Table  4).  Yet,  the CD8 § 
infiltrate was not sufficient to suppress the tumor growth. 
In contrast  to CD4 § cell depletion,  depletion of CD8 § 
cells did not interfere with IL-7-mediated tumor rejection (Fig. 
4).  Immunohistology  of regressing  tumors  from  CD8 + 
cell-depleted  mice  confirmed  the  absence  of CD8 +  and 
showed the presence of both CD4 § cells and macrophages 
(Table 4). Therefore, CD8 + cells were obviously not neces- 
sary for the tumor rejection. 
To  further  analyze  the  role  of  CK3 +  cells  in  Ib7- 
producing  tumors, J558-IL-7 cells  were injected in parallel 
30 
20 
|  J558L  A  J558-1L7  +  etCD4 
[]  J558-1L7  +  control  mAD  O  J558-1L7  +  otCD8 
4~  J558-1L7 + ~THY1  B  J558-1L7 + ~CR3 
I  I  I  I  I  I  I  I  I  I  r 
0  2  4  6  8  10  12  14  16  18  20 
Days 
Figure 4.  Kinetics of tumor growth of 4  x  106 J558-IL-7 cells in the 
presence of indicated mAbs in comparison  to J558L cells. For details on 
the application of the mAbs, see Materials and Methods. One out of three 
experiments  (Exp. 3) that are summarized  in Table 3 is shown,  Symbols 
represent  the mean  tumor size. SD was <15%  in all cases. 
1295  Hock et al. Table  4.  Composite Results of Immunohistology from 
J558-IL-7 Tumors of mAb-treated Mice 
Tumors* of mice treated with mAb against: 
Staining  Thy-  1.2  CD4  CD8  CR3 
aCD4  -~  -  +  + 
aCD8  -  +S  -  + 
aCR3  -  -  +  +/- 
* Tumors were excised in case of Thy-l.2 +, CD4 §  , and CD8 § cell 
depletion at day 14, in case of CR3 + cell depletion at day 10. 
, No positive cells were detected (c~CDS, (xCD4), or the number of 
positive cells was not increased  (aCR3) in comparison to those detected 
in J558L tumors. 
S  Number of positive cells was similar to those found in J558-IL-7 
tumors of nontreated mice. 
with the anti-CR3 mAb 5C6, which has been previously 
shown to inhibit the migration of inflammatory cells, such 
as macrophages and granulocytes in vivo (33, 36). The anti- 
CR3 treatment interfered with tumor rejection but the effect 
was  incomplete  in  comparison  to  Thy-l.2 +  or  CD4 § 
cell-depleted mice. Immunohistologic analysis on day 10 after 
tumor cell injection revealed that although decreased in number 
(Table 4),  CR3 + cells had infiltrated the J558-IL-7  tumor. 
This indicates that the anti-CR3 mAb treatment had not 
completely prevented CR3 § cell recruitment and may ex- 
plain why the inhibition of tumor rejection was incomplete. 
IL 7 Gene Transfer into a Second Tumor Cell Line of Different 
Cellular Origin Likewise Leads to Tumor Rejection.  To confirm 
the observed antitumor effect, the Ib7 gene was expressed 
in the mammary adenocarcinoma cell line TS/A, which has 
been shown to be low- or nonimmunogeneic (25).  There- 
fore, TS/A cells were transfected with plasmid pLTK-IL-7 along 
with the neomycin gene containing plasmid pWLneo, selected 
for G418  resistance,  and cloned.  Clone TS/A-IL7, which 
released 50 U/ml IL-7 in the supernatant, was injected sub- 
cutaneously into syngeneic BALB/cAnN mice at doses of 2 
￿  105 cells, and tumor progression was analyzed in com- 
parison to mice that received 2  ￿  105 parental TS/A cells. 
The mice injected with TS/A-IL-7 cells remained tumor free 
(five mice, observation time of 4 wk), whereas all TS/A-injected 
animals developed tumors within 2 wk. Additionally, TS/A- 
IL-7 cells grew as tumors in CD4 + cell-depleted mice (5/5) 
like parental TS/A cells, indicating a similar mechanism of 
tumor rejection as observed  with J558-IL-7  cells. 
Discussion 
The data presented here demonstrate that the local produc- 
tion of IL-7 obtained by gene transfer into tumor cells can 
induce an immune response  that leads to the destruction of 
an otherwise progressively growing tumor. T cells play the 
central role in the antitumor response because it is completely 
abrogated in mice depleted of T  cells. This is in agreement 
with the direct proliferative  effects on both activated CD4 § 
and CD8 + T cells described for IL-7 in vitro (4, 5) and may 
explain the observed T cell infiltrate in the tumor. Depletion 
of either T  cell subset revealed the absolute dependence of 
the IL-7-mediated antitumor effect on CD4 + cells. Further- 
more, CD4 + cells can promote tumor rejection in the ab- 
sence of CD8 § cells. In view of the in vitro data showing 
that IL-7 is a potent inducer of LAK activity of CD8 + cells 
(6,  7) and is able to induce MHC-restricted cytotoxic cells 
in vitro (7, 8), it is surprising that the CD8 + T cells do not 
decisively contribute to the antitumor response  in our ex- 
perimental  setting.  Yet,  although CD8 §  T  cells  are  not 
necessary for tumor rejection, a contribution of CD8 + cells 
can not be excluded.  Their presence in J558-IL-7 tumors of 
CD4 + cell-depleted mice could explain the slightly retarded 
growth of these tumors in comparison with tumors in mice 
depleted of both T  cell subsets  (Fig.  4). 
The potential of CD4 § T  cells to induce the reduction 
of established tumors without any requirement for cytotoxic 
T cells has previously been described by other investigators 
(37, 38) and has been explained by a delayed-type hypersensi- 
tivity (DTH)-like mechanism in which other cells like NK 
or macrophages finally destroy the tumor. Consistent with 
a DTH-like mechanism, J558-IL-7 tumors are infiltrated by 
CR3 § cells and, notably, CR3 ~ cells are absent in tumors 
of CD4 §  cell-depleted  mice.  Additionally,  an  anti-CR3 
mAb interfered with the IL-7-induced  antitumor response. 
This mAb  has been shown to block migration of CR3 § 
cells (macrophages, granulocytes, and NK cells) to the site 
of inflammation (33,  36, 39).  Since granulocytes were not 
enriched in J558-IL7 tumors, and anti-asialo GM1 treatment, 
which abrogates NK cell activity, did not interfere with J558- 
IL-7 tumor rejection (preliminary results), the effects of anti- 
CK3 mAb treatment was most likely due to the interference 
with macrophage recruitment. The incomplete abrogation 
of tumor suppression  by the anti-CK3 mAb could be ex- 
plained by the fact that infiltration by macrophages was not 
completely  inhibited  in  J558-II.~7 tumors  of  anti-CR3 
mAb-treated mice. This would not be in conflict with the 
assumption of a DTH-like mechanism because the same an- 
tibody also blocks macrophage migration in classical DTH 
only in part (39).  Alternatively, it cannot be excluded that 
further effector cells or even a direct tumoricidal activity of 
CD4 § T  cells may be responsible for the incomplete effect 
of anti-CK3 mAb treatment. 
Tumor cell-targeted gene transfer has proved to be an ex- 
tremely successful approach in search for antitumor activi- 
ties ofcytokines in vivo. In particular, this approach also facili- 
tated the analysis of the effector mechanisms responsible for 
tumor destruction and revealed characteristic differences for 
the cytokines analyzed. Yet, a final comparison of the effector 
mechanisms is  still difficult because  the cellular pathways 
leading to the tumor suppression  are not completely under- 
stood in most cases, and the experimental setting (tumor cell 
line, mouse strain, level of cytokine expression) may account 
for some of the differences. 
Nevertheless,  the requirement of CD4 § cells and the fact 
that  CD8 +  cells  are  not  necessary  for  the  II.-7-mediated 
1296  Interleukin  7 Induces CD4 § T Cell-dependent Tumor Rejection tumor suppression distinguishes I1:7 from all other cytokines 
analyzed in an  analogous form (I1:2,  I1:4,  TNF,  IFN-3,, 
G-CSF). Thus, I1:2 production by tumor cells conversely in- 
duces  an  immune response  that  requires  CD8 +  but  not 
CD4 +  T  cells  (10). Similarly,  the  rejection  of  IFN-3'- 
producing tumor cells is also dependent on cytotoxic CD8 + 
T cells (15). TNF produced by tumor cells has been shown 
to induce a host-dependent antitumor response that involves 
macrophages (17), but obviously also depends on the action 
of both CD4 + and CD8 + T cells (19). Consistently, in nude 
mice, TNF leads to tumor suppression but not complete re- 
jection (18). In contrast to these results, we could not detect 
any indication of I1:7-mediated tumor rejection in the ab- 
sence of T  cells. This also distinguishes Ib7 from I1:4 and 
G-CSF, since gene transfer experiments with these cytokines 
have shown that the respective antitumor mechanisms .were 
not impaired in athymic nude mice (13, 20). Therefore, II:7 
induces a cellular pathway leading to tumor destruction that 
has not yet been described to be activated by any other cytokine 
gene transfer into tumor cells. 
We gratefully acknowledge the excellent technical assistance of Gisela Schulz, Maria-Virgilia Odenwald, 
and Magelie G~irtner. Plasmids pBAneo, Aptagl, and cell line T/SA were kindly provided by R. Mulligan, 
J. Flanagan, and G. Forni, respectively. We also thank Hugh Rosen for kindly supplying us with the 
antibody 5C6, and M. Mielke for 2.43 ascites and advice. We thank E. Adam for typing the manuscript. 
This work was supported by a grant from the Deutsche Krebshilfe, Mildred Scheel Stiftaug, e.V. 
Address correspondence to Hanno Hock, Institut ffir Immunologic, Universit~itsklinikum  Steglitz, Freie 
Universit~it Berlin, Hindenburgdamm 27, 1000 Berlin 45, Germany. 
Received for publication 13 August  1991. 
References 
1.  Namen, A.E., A.E. Schmierer, C.J. March, R.W. Overell, L.S. 
Park, D.L. Urdal, and D.Y. Mochizuki. 1988. B cell precursor 
growth-promoting  activity. J. Exp. Med. 167:988. 
2.  Namen,  A.E.,  S.  Lupton,  K.  Hjerrild,  J.  Wignall,  D.Y. 
Mochizuchi, A. Schmierer, B. Mosley, C.J. March, D. Urdal, 
S. Gillis, D. Cosman, and R.G. Goodwin. 1988. Stimulation 
of B-ceU progenitors by cloned murine interleukin-7. Nature 
(Lond.). 333:571. 
3.  Morrissey, P.J., R.G. Goodwin, R.P. Nordan, D. Anderson, 
K.H. Grabstein, D. Cosman, J. Sims, S. Lupton, B. Acres, S.G. 
Reed, D.  Mochizuki, J.  Eisenman, P.J. Conlon,  and A.E. 
Namen. 1989. Recombinant interleukin 7, pre-B cell growth 
factor, has costimulatory activity on purified mature T cells. 
J. Exp. IVied. 169:707. 
4.  Chazen, G.D., G.M.B. Pereira, G. LeGros, S. Gillis, and E.M. 
Shevach. 1989. Interleukin 7 is a T-cell growth factor. Proc. 
Natl. Acad. Sci. USA.  86:5923. 
5.  Grabstein, K.H., A.E. Namen, K. Shanebeck,  R.F. Voice, S.G. 
Reed, and M.B. Widmer. 1990. Regulation ofT cell prolifera- 
tion by IL7. j. Immunol. 144:3015. 
6.  Lynch, D.H., and R.E. Miller. 1990. Induction  of routine 
lymphokine-activated killer cells by recombinant IL7. J. Im- 
munol. 145:1983. 
7.  Alderson, M.R., H.M. Sassenfeld, and M.B. Widmer. 1990. 
Interleukin 7 enhances  cytolytic T lymphocyte generation and 
induces lymphokine-activated  killer cells from human periph- 
eral blood. J. Exp. Med. 172:577. 
8.  Hickman, C.J., J.A. Crim, H.S. Mostowski, and J.P. Siegel. 
1990. Regulation of human cytotoxic T lymphocyte develop- 
ment by IL7. J. Immunol. 145:2415. 
9.  Alderson, M.R., T.W. Tough, S.F. Ziegler, and K.H. Grab- 
stein. 1991. Interleukin 7 induces  cytokine  secretion and tumori- 
1297  Hock et al. 
cidal activity by human peripheral blood monocytes.  J. Exlx 
Med. 173:923. 
10.  Fearon, E.R.,  D.M.  Pardoll, T.  Itaya, P.  Golumbek,  H.I. 
Levitsky,  J.W. Simons, H. Karasuyama,  B. Vogelstein, and P. 
Frost. 1990. Interleukin-2 production by tumor cells bypasses 
T helper function in the generation of an antitumor response. 
Cell. 60:397. 
11.  Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, 
and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor 
cells abrogates tumorigenicity and induces protective immu- 
nity. J. Exl~ Med. 172:1217. 
12.  Bubenik,  J., J. Simova, and T. Jandlova. 1990. Immunotherapy 
of cancer using local administration of lymphoid cells trans- 
formed by IL-2 cDNA and constitutively producing IL2. Im- 
munol. Lett. 23:287. 
13.  Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine 
interleukin-4 displays  potent anti-tumor activity in vivo. Cell. 
57:503. 
14.  Li, W., T. Diamantstein, and Th. Blankenstein. 1990. Lack 
of tumorigenicity  of interleukin  4 autocrine  growing cells seems 
related to the anti-tumor function of interleukin 4. Mol. Im- 
munol. 27:1331. 
15.  Watanabe, Y., K. Kuribayashi, S. Miyatake, K. Nishihara, E. 
Nakayama, T. Taniyama,  and T. Sakata. 1989. Exogenous ex- 
pression of mouse interferon-gamma cDNA in mouse neuro- 
blastoma C1300 ceils results in reduced tumorigenicity by aug- 
mented  anti-tumor  immunity.  Proa Natl. Acad. Sci. USA. 
86:9456. 
16.  Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, 
and  E.  Gilboa. 1990. Retroviral vector-mediated gamma- 
interferon gene transfer into tumor cells generates potent and 
long lasting antitumor immunity. Cancer Res. 50:7820. 17.  Blankenstein, Th., Z. Qin, K. Uberla, W. M~iller, H. Rosen, 
H.-D. Volk, and T. Diamantstein.  1991. Tumor suppression 
after tumor cell-targeted tumor necrosis factor oe gene transfer. 
J. Exp.  Med.  173:1047. 
18.  Teng, M.N.,  B.H.  Park, H.K. Koeppen, K.J.  Tracey, B.M. 
Fendly, and H. Schreiber. 1991. Long-term inhibition of tumor 
growth by tumor necrosis factor in the absence of cachexia 
or T-cell immunity. Proc. Natl. Acad. Sci. USA.  88:3535. 
19.  Asher, A.L., J.J. Muld, A. Kasid, N.P. Restifo,  J.C. Salo, C.M. 
Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S.A. Rosen- 
berg. 1991. Murine tumor cells transduced with the gene for 
tumor necrosis factor-o~  j.  Immunol.  146:3227. 
20.  Colombo, M.P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. 
Rodolfo, E Mavilio,  and G. Parmiani. 1991. Granulocyte  colony- 
stimulating factor gene transfer suppresses tumorigenicity of 
a murine  adenocarcinoma in vivo. J. Exp.  Med.  173:889. 
21.  Forni, G., M. Giovarelli, and A. Santoni. 1985. Lymphokine 
activated tumor inhibition in vivo. I. The local administration 
ofinterleukin-2 triggers nonreactive lymphocytes from tumor 
bearing mice to inhibit  tumor growth in vivo. j.  Imrnunol. 
134:1305. 
22,  Torre-Amione, G., R.D. Beauchamp, H. Koeppen, B.H. Park, 
H. Schreiber, H.L. Moses, and D.A. Rowley. 1990. A highly 
immunogenic tumor transfected with a murine transforming 
growth factor type 81 eDNA escapes immune  surveillance. 
Proc. Natl. Acad. Sci. USA.  87:1486. 
23.  Blankenstein,  T.,  D.A.  Rowley, and  H.  Schreiber.  1991. 
Cytokines and cancer; experimental systems. Cuw. Opin. Im- 
munol. In press. 
24.  Oi, V.T., S.L. Morrison, L.A. Herzenberg, and P. Berg. 1983. 
Immunoglobulin expression  in transformed  lymphoid cells. Proa 
Natl.  Acad. Sci. USA.  80:825. 
25.  Nanni, P., C. De Giovanni, P.L. Lollini, G. Nicoletti,  and G. 
Prodi.  1983. TS/A: a new metastasizing cell line originated 
from a BALB/c spontaneous mammary adenocarcinoma. Clin. 
Extx  Metastasis. 1:373. 
26.  Innis, M.A., D.H. Gelftand,  J.J. Snisky, and T.J. White. 1990. 
PCR Protocols: A Guide to Methods and Application. Aca- 
demic Press, New York. 
27.  Wilson, J.M., D.E. Johnston, D.M. Jefferson, and R.C. Mul- 
ligan. 1988. Correction of the genetic defect in hepatocytes 
from the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. 
Acad. Sci. USA.  85:4421. 
28.  Flanagan, J.G., and P. Leder. 1990. The kit ligand: a cell sur- 
face molecule altered in steel mutant fibroblast. Cell. 63:185. 
29.  Conlon,  P.J., P.J. Morrissey, R.P. Nordan,  K.H. Grabstein, 
K.S. Prickett, S.G. Reed, R. Goodwin, D. Cosman, and A.E. 
Namen. 1989. Murine thymocytes proliferate  in direct response 
to interleukin-7. Blood. 74:1368. 
30.  Ledbetter,  J.A., and L.A. Herzenberg. 1979. Xenogeneic  mono- 
clonal antibodies to mouse lymphoid differentiation antigens. 
Immunol.  Rev. 47:63. 
31.  Dialynas, D.M., Z.S. Quan, K.A. Wall, A. Pierres,  J. Quintans, 
M.R. Loken, M. Pierres, and F. Fitch. 1983. Characterization 
of the  murine  T  cell surface molecule, designated  L3T4, 
identified by the monoclonal antibody  GK1.5. J.  ImmunoL 
131:2445. 
32.  Sarmiento, M., A. Glasebrook, and F. Fitch. 1980. IgG or IgM 
monoclonal antibodies reactive with different determinants on 
the molecular complex Lyt-2 antigen block T cell-mediated 
cytolysis  in the absence of complement.J. Immunol.  125:2665. 
33.  Rosen, H., and S. Gordon. 1987. Monoclonal antibody to the 
murine type 3 complement receptor inhibits adhesion of my- 
elomonocytic cells in vitro and inflammatory cell recruitment 
in vivo. j.  Exp.  Med.  166:1685. 
34.  Ho, M.K., and T.A. Springer. 1982. Mac-1 antigen: quantita- 
tive expression  in macrophage populations and tissues, and im- 
munofluorescent localization in spleen.J, lmmunol.  128:2281. 
35.  CordeU,  U.L., B. Falini, W.N. Erber, A.K. Gosh, Z. Abdulaziz, 
S. MacDonald, K.A.E Pulford, H. Stein, and D.Y. Mason. 1984. 
Immunoenzymatic  labeling of monoclonal antibodies using 
immune complexes of alkaline phosphatases and monoclonal 
anti-alkaline  phosphatase  (APAAP complexes).  Histochern. 
Cytochem.  32:219. 
36.  Rosen, H., G. Siamon, and R.J.  North. 1989. Exacerbation 
of murine listeriosis by a monoclonal antibody specific  for the 
type 3 complement receptor of myelomonocytic cells.  J. Exp. 
Med.  170:27. 
37.  Fujiwara, H., M. Fukuzawa, T. Yoshioka, H. Nakajima, and 
T. Hamoaka.  1984. The role of tumor-specific LYT-I+2-  T 
cells in eradicating tumor cells in vivo.J. Irnmunol. 133:1671. 
38.  Greenberg, P.D., D.E. Kern, and M.A. Cheever. 1985. Therapy 
of disseminated murine leukemia with cyclophosphamide and 
immune LYT-1  +, 2-  T cells.  J. Extx  Med.  161:1122. 
39.  Rosen, H., G. Miton, and S. Gordon. 1989. Antibody to the 
murine type 3 complement receptor inhibits T lymphocyte- 
dependent recruitment of myelomonocytic  cells in vivo.J. Exp. 
Med.  169:535. 
1298  Interleukin  7 Induces CD4 § T Cell-dependent Tumor Rejection 